Canaccord lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $11 from $12 and keeps a Buy rating on the shares. The firm believes TriSalus has the foundation of a strong medical device business with a commercial footprint and catalysts to support it including new product launches and clinical data.
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
TriSalus Life Sciences price target lowered to $11 from $12 at Canaccord
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App